A Trial of PF-06252616 in Ambulatory Participants With LGMD2I
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02841267 |
Recruitment Status :
Completed
First Posted : July 22, 2016
Results First Posted : October 19, 2020
Last Update Posted : October 19, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
The investigational product PF 06252616, a humanized anti myostatin monoclonal antibody that neutralizes myostatin (GDF8) is in development for the treatment of Limb Girdle Muscular Dystrophy 2I (LGMD2I) to preserve and/or improve muscle function.
This study will provide the clinical assessment of the safety, tolerability, Pharmacokinetics and Pharmacodynamics of PF 06252616 following repeat IV doses in ambulatory adults with LGMD2I.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
LGMD2I | Drug: PF 06252616 | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 19 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1b/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Ambulatory Participants With LGMD2I |
Study Start Date : | July 2016 |
Actual Primary Completion Date : | January 2019 |
Actual Study Completion Date : | January 2019 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Low Dose, Cohort 1
4 subjects will be enrolled in cohort 1 and will receive an initial dose of 5mg/kg PF 06252616 IV every 4 weeks. Following 32 weeks of treatment and a safety review, if no stopping rules have been met, subjects will be receive an additional 32 weeks of treatment with 40 mg/kg PF 06252616 IV every 4 weeks.
|
Drug: PF 06252616 |
Active Comparator: Middle dose, Cohort 2
8 subjects will be enrolled in cohort 2 and receive 20 mg/kg of PF 06252616 IV every 4 weeks for 32 weeks.
|
Drug: PF 06252616 |
Active Comparator: High dose, Cohort 3
8 subjects will be enrolled in cohort 3 and receive 40 mg/kg of PF06252616 IV every 4 weeks for 32 weeks.
|
Drug: PF 06252616 |
- Incidence of Dose Limiting or Intolerability Treatment Related Adverse Events [ Time Frame: Baseline through 64 weeks ]Adverse events include subject-reported symptoms as well as clinically-significant changes in laboratory testing, vital signs, and suicide screening (based on the Columbia Suicide Severity Rating Scale).
- Maximum Observed Serum Concentration at Steady State (Cmax, ss) of GDF-8 [ Time Frame: Day 337 and Day 393 for Cohort 1; Day 113 and 169 for Cohorts 2 and 3 ]The concentration of myostatin (GDF-8) was measured in serum 2 hours after dose administration at two visits (Day 337 and Day 393 for Cohort 1; Day 113 and 169 for Cohorts 2 and 3)where drug concentration had reached steady state. The highest concentration from these two time points was averaged for each cohort.
- Minimum Observed Serum Trough Concentration at Steady State (Ctrough,ss) of GDF-8 [ Time Frame: Day 337 and Day 393 for Cohort 1; Day 113 and 169 for Cohorts 2 and 3 ]The concentration of myostatin (GDF-8) was measured in serum prior to dose administration at two time points (Day 337 and Day 393 for Cohort 1; Day 113 and 169 for Cohorts 2 and 3) where drug concentration had reached steady state. The lowest concentration from these two time points was averaged for each cohort.
- Maximum Observed Serum Concentration (Cmax) of PF-06252616 [ Time Frame: Day 113 and Day 169 ]The peak concentration of study drug (PF-06252616) was measured in serum following dose administration at two time points (Day 113 and Day 169) where drug concentration had reached steady state. The higher concentration from these two time points was averaged for each cohort.
- Minimum Observed Serum Trough Concentration (Ctrough) of PF-06252616 [ Time Frame: Day 113 and Day 169 ]The peak concentration of study drug (PF-06252616) was measured in serum prior to dose administration at two time points (Day 113 and Day 169) where drug concentration had reached steady state. The lower concentration from these two time points was averaged for each cohort.
- Immunogenicity: Incidence of Anti-drug Antibody [ Time Frame: Baseline through 96 weeks ]Blood samples were tested for the presence of anti-drug antibodies prior to the initiation of study drug, at dose escalation (Cohort 1 only), and at 3 separate time points after the last dose was given.
- Mean Change From Baseline in 10 Meter Walk/Run Time in Seconds [ Time Frame: Baseline through 32 weeks ]Subjects are asked to run or walk as quickly as possible for 10 meters from a standing position. The total time to traverse 10 meters is recorded in seconds.
- Mean Change From Baseline of Forced Vital Capacity in Liters [ Time Frame: Baseline through 32 weeks ]The total forced vital capacity was measured using a bedside spirometer. The best of 3 trials was recorded.
- Mean Change From Baseline in 2MWD in Meters [ Time Frame: Baseline through 32 weeks ]Average change in distance (in meters) walked in 2 minutes.
- Mean Change From Baseline in TUG in Seconds [ Time Frame: Baseline through 32 weeks ]The timed-up-and-go test (TUG) is the total time it takes the subject to rise from a seated position, walk to a marker 3 meters away, return to the chair, and sit.
- Mean Change From Baseline in Muscle Strength as Measured by Modified MRC Scale [ Time Frame: Baseline through 32 weeks ]Twenty-two muscle groups were measured on a modified MRC scale ranging from 1 through 12. The total scores from all 22 muscle groups were added to generate a summary score ranging from 12 to 264 with higher scores signifying greater strength. The change in summary score was calculated over the first 32 weeks of treatment.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 99 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male and female patients age ≥ 18
- Diagnosis of LGMD2I as defined by clinical presentation consistent with LGMD2I and FKRP gene testing showing biallelic alterations known or likely to be pathogenic. Diagnosis must be confirmed in subject's medical history and by genetic testing obtained during routine clinical care for diagnostic purposes as reported from an appropriate regulated laboratory using a clinically validated genetic test (genetic testing is not provided by the sponsor).
- Ability to walk/run 10m
- Ability to rise from chair
- Adequate hepatic and renal function on screening laboratory assessments
- Iron content estimate on the screening liver MRI within the normal range as determined by R2* value (R2* ≤ 139 Hz at 3.0T).
- Participant must provide written informed consent for participating in study.
- Participant must possess the ability, per the Principal Investigator (PI), to understand and comply with protocol instruction for the entire duration of the study.
Exclusion Criteria:
- Known cognitive impairment or behavioral issues that would impede the ability to provide informed consent or to follow study instructions.
- History of major surgical procedure within 6 weeks of signing the informed consent or planned surgery during the study.
- Any injury which may impact functional testing. Previous injuries must be fully healed prior to consent. Prior lower limb fractures must be fully healed and at least 3 months from injury dates.
- Previous treatment with another investigational product within 30 days or 5 half-lives, (whichever is longer) prior to consenting.
- Corticosteroid treatment within 3 months prior to consenting.
- Compromised cardiac function (left ventricular ejection fraction <50%).
- Unwilling or unable (e.g. metal implants, requires sedation) to undergo examination with closed MRI without sedation.
- History of allergic or anaphylactic reaction to a therapeutic or diagnostic protein.
- Female subjects who are pregnant or nursing.
- Subjects who, are biologically capable of having children who are unwilling or unable to use highly effective methods of contraception (as outlined in this protocol) during sexual activity for the duration of the study and through completion of final study visit.
- Predisposition to iron accumulation. (Serum iron >1.2 X ULN, serum ferritin >1.2 ULNN).
- Underlying disposition for bleeding disorder on screening laboratory assessment (PT/INR>1.25 X ULN, aPTT > 1.25 ULN, fecal occult blood is positive)
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic, or allergic disease.
- Unwillingness or inability to comply with the requirements of this protocol (in the opinion of the PI) including, but not limited to, the presence of any condition (physical, mental, or social) that is likely to affect the participant's ability to return for study visits or adhere to the visit schedule.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02841267
United States, Maryland | |
Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | |
Baltimore, Maryland, United States, 21205 |
Principal Investigator: | Kathryn R Wagner, MD/PhD | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. |
Documents provided by Kathryn Wagner, Hugo W. Moser Research Institute at Kennedy Krieger, Inc.:
Responsible Party: | Kathryn Wagner, Director, Center for Genetic Muscle Disorders, Hugo W. Moser Research Institute at Kennedy Krieger, Inc. |
ClinicalTrials.gov Identifier: | NCT02841267 |
Other Study ID Numbers: |
WI203720 |
First Posted: | July 22, 2016 Key Record Dates |
Results First Posted: | October 19, 2020 |
Last Update Posted: | October 19, 2020 |
Last Verified: | September 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |